Endonovo Therapeutics, Inc. (ENDV) stock
ENDVOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q3 FY2023, quarter ended Sep 30, 2023Last filing: 10-Q/A on Dec 29, 2023
$0.00+0.00 (0.00%)
Close on Oct 19, 2026Market cap $135.08KP/E –Yield –
Endonovo Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Endonovo Therapeutics's operating cash flow for the twelve months ending Sep 30, 2023 was -$629.90K. For fiscal 2022 it was -$678.84K. The highest annual figure on record is $8.50K in fiscal 2010.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | -$678.84K | – |
| FY2021 | Dec 31, 2021 | -$986.58K | – |
| FY2020 | Dec 31, 2020 | -$741.59K | – |
| FY2019 | Dec 31, 2019 | -$2.54M | – |
| FY2018 | Dec 31, 2018 | -$2.88M | – |
| FY2017 | Dec 31, 2017 | -$2.99M | – |
| FY2016 | Dec 31, 2016 | -$2.46M | – |
| FY2015 | Dec 31, 2015 | -$1.02M | – |
| FY2014 | Dec 31, 2014 | -$909.30K | – |
| FY2013 | Dec 31, 2013 | -$257.42K | – |
| FY2012 | Dec 31, 2012 | -$284.89K | – |
| FY2011 | Dec 31, 2011 | -$50.35K | -692.3% |
| FY2010 | Dec 31, 2010 | $8.50K | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2023 | Sep 30, 2023 | -$65.37K | – |
| Q2 FY2023 | Jun 30, 2023 | -$165.84K | – |
| Q1 FY2023 | Mar 31, 2023 | -$173.16K | – |
| Q4 FY2022 | Dec 31, 2022 | -$225.54K | – |
| Q3 FY2022 | Sep 30, 2022 | -$123.86K | – |
| Q2 FY2022 | Jun 30, 2022 | -$206.48K | – |
| Q1 FY2022 | Mar 31, 2022 | -$122.95K | – |
| Q4 FY2021 | Dec 31, 2021 | -$391.30K | – |
| Q3 FY2021 | Sep 30, 2021 | -$169.41K | – |
| Q2 FY2021 | Jun 30, 2021 | -$135.93K | – |
| Q1 FY2021 | Mar 31, 2021 | -$289.95K | – |
| Q4 FY2020 | Dec 31, 2020 | -$192.86K | – |
| Q3 FY2020 | Sep 30, 2020 | -$96.67K | – |
| Q2 FY2020 | Jun 30, 2020 | -$154.85K | – |
| Q1 FY2020 | Mar 31, 2020 | -$297.22K | – |
| Q4 FY2019 | Dec 31, 2019 | -$308.38K | – |
| Q3 FY2019 | Sep 30, 2019 | -$1.02M | – |
| Q2 FY2019 | Jun 30, 2019 | -$687.62K | – |
| Q1 FY2019 | Mar 31, 2019 | -$528.23K | – |
| Q4 FY2018 | Dec 31, 2018 | -$716.10K | – |
| Q3 FY2018 | Sep 30, 2018 | -$830.38K | – |
| Q2 FY2018 | Jun 30, 2018 | -$741.61K | – |
| Q1 FY2018 | Mar 31, 2018 | -$590.75K | – |
| Q4 FY2017 | Dec 31, 2017 | -$800.57K | – |
| Q3 FY2017 | Sep 30, 2017 | -$841.36K | – |
| Q2 FY2017 | Jun 30, 2017 | -$913.65K | – |
| Q1 FY2017 | Mar 31, 2017 | -$434.19K | – |
| Q4 FY2016 | Dec 31, 2016 | -$658.65K | – |
| Q1 FY2016 | Jun 30, 2016 | -$1.03M | – |
| Q1 FY2015 | Mar 31, 2015 | -$193.84K | – |
| Q4 FY2014 | Dec 31, 2014 | -$227.73K | – |
| Q3 FY2014 | Sep 30, 2014 | -$196.10K | – |
| Q2 FY2014 | Jun 30, 2014 | -$289.53K | – |
| Q1 FY2014 | Mar 31, 2014 | -$195.93K | – |
| Q4 FY2013 | Dec 31, 2013 | -$53.67K | – |
| Q3 FY2013 | Sep 30, 2013 | -$28.16K | – |
| Q2 FY2013 | Jun 30, 2013 | -$59.36K | – |
| Q1 FY2013 | Mar 31, 2013 | -$116.23K | – |
See a number that looks wrong?